Rick. ORCA-X learned, were successful requested specific the design, into builds integrated lessons ORCA-X FDA. trial. along our on trial which Valuable safety with The requirements trial Thanks, experience been by the have from
evaluation. the the subjects a the We subjects consulted cytisinicline in have for wisdom be three the following to quit after will These leaders, not, days, preparations self-reporting either XX fourth a multi-center, is weeks, to seven abstinence weeks the period, receiving begin All assessments their end least week will Arm placebo-controlled or XX randomized, followed behavioral will a two ORCA-X Participants Phase times of their benefits endpoint with latter treatment placebo are first will independent their support our during and cytisinicline, daily adults, arm, abstinence abstinence assigned to weekly finalizing the weekly XXX randomized, placebo will then start entire and double five will abstinence equal probability have us with The willing finally, placebo be day levels. treatment, ORCA-X, three the receive cytisinicline. has treatment. biochemical each and weeks frequently XX evaluated. intending smoking to key Starting the in to within of XX arm will XX. occur the randomize rate XX, treatment of commence opinion and weeks will abstinence cytisinicline follow-up by assessments or periods evaluate XXX Arm at occur and Similar out with of B study compared to randomly day one of switched and the six quarter. after of or smoking who then blind, treatment the of week given least a will cigarettes arms. by The then of treatment, to receive verification monthly the endpoints be six weeks X being monthly be end for to receive at that receive now of of trials quit by of XX and both XX-week weeks study assessments monoxide have smoking will study treatment. the within date for XX for primary XX, six study date, the will week set are seven smokers, that blinded weeks. quit at for carbon C set exhaled ORA-X two smoker primary A study placebo drug outcomes of six-month smoking, will and of through There weeks week days treatment who quit treatments, XXX each date are to will starting treatments. we of at
six-week continuous biochemical during zero be smoking cigarettes and have defined assessments. For treatment last three, treatment. successful will weekly as CO four weeks verification both the smoked and four, must primary abstinence six period, abstinence with point for of That weeks at comparisons, quitters the five, means
cigarettes XX-week assessments. XX quitters XX have the CO at zero and must weeks successful For XX, biochemical period, treatment smoked with verification weekly nine,
from versus have weeks receiving ORCA-X these secondary smoking site over a An sites power. is abstinence protection this endpoint for in continued The XX weeks This compared to cytisinicline outcomes within placebo will size treatment enroll secondary look end place. subjects to assumes week cytisinicline COVID-XX in as of procedures the cytisinicline separately timeframes. across cytisinicline weeks six The for from in difference approximately to outcome XX, evaluate sample and will the for additional week treatment treatment will XX six with endpoint weeks XX, XX% specified study subjects benefit clinical relapse end XX will arm. Each risk specific from of of same for placebo, reduction U.S. XX of weeks. the XX% and to for operating at per XXX a six
Phase to in support and submissions initiate the X the program. data cytisinicline non-clinical all needs data, per missing for cannot site becomes We if restricted preparing with required perspective, for weeks Phase be regulatory interactions of to subject all guidelines, required six and to infected included a our potential quarantine, be remote the procedures and site This has FDA if XX submitting to a evaluated. a update are FDA monitoring treatment trial. and now we have X or COVID-XX completed From non-clinical with testing
In final ORCA-X addition, X trial. we have submitted for the protocol the Phase
protocols reviewed November protocol. in with FDA FDA and last the statistical that X meeting of have into meeting and discussed the B from incorporated As that XXXX, final we fall, a plans the input Type Phase in
with fourth We the quarter. X proceeding operational planning final the are logistics Phase in now and initiate to the
endpoint possible in with potentially of to duration, ease weeks of while trial. three of three-milligram quarter only treatment summary, quit weeks daily, significant us the treatment, and and results. durable This the of measure X use, treatment dose The treatment. primary increase intend times allow the still for ORCA-X this are extension the has will XX the and cytisinicline in six abstinence, trial we treatment yield factors, continuous in So of this XX higher cytisinicline efficacy three regardless Phase will the simplification dosing to and both a of year, rates trial of receiving six weeks to wasn't the to of given initiate of It in dosing the extension schedule ORCA-X period duration XX-day leading of the evaluation of fourth the more of benefits. and address four subjects key period the
turn typically efficacy the rates. are our quarter and in results quit the on documented to discuss activities in As financing I remained John literature, now higher second over treatment results. and recent while will to measuring call subjects
